# US 2013/0156750 A1 · Compositions and Methods for Using Human YKL-40 to Treat Acute Lung Injury > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0156750 A1 - Document ID: US20130156750A1 - Status: Published application - Kind: A1 - Application number: 13/704,400 - Filed: 2011-06-16 - Published: 2013-06-20 - Earliest claimed: 2010-06-16 - Assignees: Yale University - Inventors: Jack A. Elias - Web page: https://patentgrep.com/patent/US20130156750A1 ## CPC - A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases - C12N 9/2442: {Chitinase (3.2.1.14)} - C12Q 1/34: involving hydrolase - C12Y 302/01014: Chitinase (3.2.1.14) - G01N 2333/924: acting on glycosyl compounds (3.2) - G01N 2800/12: Pulmonary diseases - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - G01N 2800/56: Staging of a disease; Further complications associated with the disease - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - C12Y: ENZYMES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The invention includes methods of treating oxidant-mediated acute lung injury in a subject by administration of a chitinase-like protein molecule, or an activator thereof. The invention also includes methods of assessing the level of a chitinase-like protein molecule in a subject as a marker of the prognosis of a subject suffering from acute lung injury. ## Claims ### Claim 1 A method of treating acute lung injury in a subject, said method comprising administering an effective amount of a chitinase-like protein molecule, or activator thereof, to said subject, thereby treating said acute lung injury. ### Claim 2 (depends on 1) The method of claim 1, wherein said chitinase-like protein molecule is YKL-40. ### Claim 3 (depends on 1) The method of claim 1, wherein said acute lung injury is oxidant-mediated acute lung injury. ### Claim 4 (depends on 1) The method of claim 1, wherein said subject is a human. ### Claim 5 A method of preventing acute lung injury in a subject, said method comprising administering an effective amount of a chitinase-like protein molecule, or activator thereof, to said subject, thereby preventing said acute lung injury. ### Claim 6 (depends on 5) The method of claim 5, wherein said chitinase-like protein molecule is YKL0-40. ### Claim 7 (depends on 5) The method of claim 5, wherein said acute lung injury is oxidant-mediated acute lung injury. ### Claim 8 (depends on 5) The method of claim 5, wherein said subject is a human. ### Claim 9 A method of determining the severity of acute lung injury in a subject, the method comprising: a. obtaining a sample from the subject, wherein the subject has, or is suspected of having, acute lung injury, b. determining in the sample the level of at least one chitinase-like protein molecule, c. comparing the level of the at least one chitinase-like protein molecule in the sample with the level in a control or reference standard, wherein the difference in the level of the at least one chitinase-like protein molecule between the sample and the control or reference standard is a measure of the severity of acute lung injury in the subject. ### Claim 10 (depends on 9) The method of claim 9, wherein said chitinase-like protein molecule is YKL0-40. ### Claim 11 (depends on 9) The method of claim 9, wherein said acute lung injury is oxidant-mediated acute lung injury. ### Claim 12 (depends on 9) The method of claim 9, wherein said subject is a human. ### Claim 13 A method of evaluating the progression of acute lung injury in a subject, the method comprising: a. obtaining a sample from the subject, wherein the subject has, or is suspected of having, acute lung injury, b. determining in the sample the level of at least one chitinase-like protein molecule, c. comparing the level of the at least one chitinase-like protein molecule in the sample with the level in a control or reference standard at a first time point, d. comparing the level of the at least one chitinase-like protein molecule in the sample with the level in a control or reference standard at a second time point, wherein the difference in the level of the at least one chitinase-like protein molecule between the sample and the control or reference standard at the first time point and the second time point is a measure of the progression of acute lung injury in the subject. ### Claim 14 (depends on 13) The method of claim 13, wherein said chitinase-like protein molecule is YKL-40. ### Claim 15 (depends on 13) The method of claim 13, wherein said acute lung injury is oxidant-mediated acute lung injury. ### Claim 16 (depends on 13) The method of claim 13, wherein said subject is a human. ### Claim 17 A method of evaluating the effect of a treatment of acute lung injury in a subject, the method comprising: a. obtaining a sample from the subject, wherein the subject has, or is suspected of having, acute lung injury, b. determining in the sample the level of at least one chitinase-like protein molecule, c. comparing the level of the at least one chitinase-like protein molecule in the sample with the level in a control or reference standard before treatment, d. comparing the level of the at least one chitinase-like protein molecule in the sample with the level in a control or reference standard after treatment, wherein the difference in the level of the at least one chitinase-like protein molecule between the sample and the control or reference standard before treatment and after treatment is a measure of the effect of the treatment of acute lung injury on the subject. ### Claim 18 (depends on 17) The method of claim 17, wherein said chitinase-like protein molecule is YKL-40. ### Claim 19 (depends on 17) The method of claim 17, wherein said acute lung injury is oxidant-mediated acute lung injury. ### Claim 20 (depends on 17) The method of claim 17, wherein said subject is a human.